Form 8-K BIOCRYST PHARMACEUTICALS For: Nov 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
BioCryst Pharma (BCRX) PT Raised to $21 at Piper Sandler, 'we continue to recommend shares'
November 4, 2024 2:20 PM ESTPiper Sandler analyst Tyler Van Buren raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $21.00 (from $20.00) while maintaining a Overweight rating.
The analyst comments "Remain OW rated on BCRX shares after this mornings Q324 Orladeyo beat and narrowed FY24 Orladeyo revenue... More
BofA Securities on BioCryst Pharma (BCRX) 'Stock’s weakness offers particularly attractive entry point'
November 4, 2024 2:06 PM EST(Updated - November 4, 2024 2:16 PM EST)
BofA Securities analyst Tazeem Ahmad reiterated a Buy rating and $11.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "BCRX reported $116.3mn in 3Q Orladeyo sales, slightly ahead of our $113.7mn and consensus $112.6mn. Mgmt highlights strong patient demand, noting US start forms were up 14.2% over the past 12 months and the paid drug rate improved to 74.8% (2Q: 74.4%). Additionally, 67 new US prescribers were added in 3Q, which is the highest add in the past eight quarters. The company narrowed FY24 Orladeyo sales guidance to... More
